v3.24.1.u1
Consolidated Statements of Convertible Redeemable Preferred Stock and Stockholders’ Equity (Deficit) - USD ($)
Series B
Preferred Stock
Series Seed
Preferred Stock
Series A
Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Other Comprehensive Income
Total Onconetix Equity (Deficit)
Non-controlling Interest
Total
Balance at Dec. 31, 2021 $ 11   $ 32 $ 7,403,204 $ (5,956,670) $ 1,446,577   $ 1,446,577
Balance (in Shares) at Dec. 31, 2021 1,146,138   3,200,000              
Foreign currency translation adjustment                    
Issuance of common stock in initial public offering, net of $2.9 million of offering costs $ 22 17,138,818   17,138,840   17,138,840
Issuance of common stock in initial public offering, net of $2.9 million of offering costs (in Shares)       2,222,222            
Conversion of convertible preferred stock to common stock upon initial public offering $ (11)   $ 56 (45)    
Conversion of convertible preferred stock to common stock upon initial public offering (in Shares) (1,146,138)   5,626,365            
Issuance of common stock and warrants in April private placement, net of $1.1 million of offering costs $ 6 6,858,322   6,858,328   6,858,328
Issuance of common stock and warrants in April private placement, net of $1.1 million of offering costs (in Shares)       590,406            
Issuance of common stock and warrants in August private placement, net of $2.2 million of offering costs $ 14 8,689,302   8,689,316   8,689,316
Issuance of common stock and warrants in August private placement, net of $2.2 million of offering costs (in Shares)       1,350,000            
Exercise of stock options $ 2 1,653   1,655   1,655
Exercise of stock options (in Shares)       165,452            
Exercise of pre-funded warrants $ 22 1,414   1,436   1,436
Exercise of pre-funded warrants (in Shares)       2,277,046            
Issuance of restricted stock $ 3 263,921   263,924   263,924
Issuance of restricted stock (in Shares)       293,466            
Stock-based compensation   1,974,566   1,974,566   1,974,566
Stock-based compensation (in Shares)                    
Purchase of treasury shares     $ (566,810)     (566,810)   (566,810)
Purchase of treasury shares (in Shares)         (459,729)          
Net loss (13,419,830) (13,419,830) (13,419,830)
Balance at Dec. 31, 2022 $ 157 42,331,155 $ (566,810) (19,376,500) 22,388,002   22,388,002
Balance (in Shares) at Dec. 31, 2022 15,724,957   (459,729)          
Issuance of common stock from exercise of preferred investment options $ 25 2,272,813   2,272,838   2,272,838
Issuance of common stock from exercise of preferred investment options (in Shares)       2,486,214            
Issuance of warrants for settlement of contingent warrants   129,184   129,184   129,184
Issuance of warrants for settlement of contingent warrants (in Shares)                    
Issuance of Series A Preferred Stock   3,490,000   3,490,000   3,490,000
Issuance of Series A Preferred Stock (in Shares)     3,000              
Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction $ 64,236,085 $ 37 875,447   875,484   875,484
Issuance of common stock and Series B Preferred Stock in connection with PMX Transaction (in Shares) 2,696,729   3,675,414            
Assumption of stock-based compensation plan awards in connection with PMX Transaction         7,006,504 7,006,504
Assumption of stock-based compensation plan awards in connection with PMX Transaction (in Shares)                  
Forfeitures of restricted stock   $ (3) 3      
Forfeitures of restricted stock (in Shares)       (250,110)            
Foreign currency translation adjustment       2,374,957 2,374,957   2,374,957
Foreign currency translation adjustment (in Shares)                  
Changes in pension benefit obligation             5,963 5,963   5,963
Exercise of stock options 459   459   459
Exercise of stock options (in Shares)       45,920            
Exercise of pre-funded warrants $ 7 (7)      
Exercise of pre-funded warrants (in Shares)       646,640            
Issuance of restricted stock $ 5 (5)      
Issuance of restricted stock (in Shares)       512,940            
Stock-based compensation   329,760   329,760   329,760
Stock-based compensation (in Shares)                    
Purchase of treasury shares     $ (58,981)     (58,981)   (58,981)
Purchase of treasury shares (in Shares)         (57,670)          
Net loss (37,409,694) (37,409,694) (37,409,694)
Balance at Dec. 31, 2023 $ 64,236,085 $ 228 $ 49,428,809 $ (625,791) $ (56,786,194) $ 2,380,920 $ (5,602,028) $ 7,006,504 $ 1,404,476
Balance (in Shares) at Dec. 31, 2023 2,696,729 3,000 22,841,975   (517,399)